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Background-—China is experiencing a marked increase in ST-segment elevation myocardial infarction hospitalizations, with 30%
occurring among women and higher risk of in-hospital death in relatively younger age groups (<70). Yet, little is known about sex
differences in ST-segment elevation myocardial infarction presentation and management.
Methods and Results-—In a nationally representative sample of patients with ST-segment elevationmyocardial infarction admitted to
162 Chinese hospitals in 2001, 2006, and 2011, we examined sex differences in hospitalization rates, clinical profiles, and quality of
care. Among 11 986 patients, the proportion of women was unchanged between 2001 and 2011. The estimated national rates of
hospital admission per 100 000 people increased from 4.6 in 2001 to 18.0 in 2011 amongmen (3.9-fold increase) and from 1.9 to 8.0
among women (4.2-fold increase) (Ptrend<0.0001). The median age of women increased from 68 years in 2001 to 72 years in 2011
(Ptrend<0.001); however, there was no age change in men (63 years in 2011) (Ptrend=0.48). After accounting for age, women had a
higher frequency of comorbidities. Although there were significant sex differences in the time interval of >12 hours between symptom
onset and admission time in 2001, since 2006 delays in presentation were comparable between women and men. Fewer women
without contraindications received evidence-based therapies than men, including reperfusion (57.5% versus 44.2%), early aspirin
(88.8% versus 85.9%), and clopidogrel (56.9% versus 52.5%, P<0.001 for all) and the differences were largely unchanged over time.
Conclusions-—Women experienced a higher increase in hospitalization rates for ST-segment elevation myocardial infarction in
China between 2001 and 2011 and were less likely to receive evidence-based therapies, especially reperfusion. In addition to
efforts to improve quality of care generally, understanding the reasons for this sex disparity and addressing these differences in
care should be a priority.
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ORIGINAL RESEARCH
A s part of China’s epidemiologic transition to higher ratesof noncommunicable diseases, women, like men, are
experiencing a rapid increase in the incidence of acute
myocardial infarction (AMI) and AMI-related mortality,1 as
seen in other low- and middle-income countries.2 In addition,
the China Patient-centered Evaluative Assessment of Cardiac
Events (PEACE) study demonstrated sex differences in
mortality with women at higher risk of death in younger age
groups.3 Yet, much less is known about whether sex
differences in clinical profiles and care quality differ between
men and women and, if so, whether these differences are
explained by age, and how they change over time.
Understanding sex differences in the clinical presentation
and quality of care for high-impact conditions like AMI is
instrumental to the prioritization of resources for quality
improvement programs. A recognition of sex differences
in the treatment of myocardial infarction in the late 1990s
and early 2000s4–6 in the United States led to national
campaigns7 and female-specific guidelines.8–10 Subse-
quently, sex gaps in care have narrowed over time.5,11
Previous studies in China demonstrate similar sex differ-
ences in treatment of comorbidities and outcomes.3,12–14
However, these studies were generally limited to single sites
or centers located predominantly in urban areas and
examined single points in time, warranting a national
perspective on sex differences in clinical presentation and
quality of care in China.12,13 Moreover, given that women
are older than men at the time of an AMI,3,15 it remains
unknown whether these differences could be explained by
age or how sex-based differences have changed over the
last decade during improved access and healthcare quality in
China.16
To provide insights into differences in patient character-
istics and quality of care over time between men and women,
we analyzed data from the China PEACE Retrospective AMI
Study,17 which included a random nationally representative
sample of patients with AMI from 63 urban and 99 rural
hospitals across China in 2001, 2006, and 2011. We have
previously shown women in the younger age group had higher
in-hospital mortality. In this study, our primary aim is to
investigate sex differences in the presenting characteristics
and quality of care of patients with ST-segment elevation
myocardial infarction (STEMI), whether these differences




The objectives, scope, and purpose of the China PEACE
Retrospective AMI Study have been described previously.17
In brief, using 2-stage random sampling, a nationally
representative sample of patients admitted with AMI in
2001, 2006, and 2011 was obtained. We stratified the
hospitals into 5 economic–geographical regions (eastern
rural, central rural, western rural, eastern urban, and central–
western urban) since hospital volumes and clinical capacities
differ between urban and rural areas and between the 3
official economic–geographical regions (eastern, central, and
western) of China. We used systematic random sampling
procedures to select patients with AMI from the local
hospital database of each sampled hospital in each study
year. We used version 9 (410.xx) and version 10 (I21.xx;
when available) ICD codes to screen for possible cases of
AMI. These cases were then further confirmed by clinical
record assessment. Detailed clinical data were then collected
by data abstraction to identify those cases that represented
initial AMI episodes according to the definition in the 2010
China National Guideline for STEMI.18 The central ethics
committee at the National Center for Cardiovascular
Diseases approved the study. All collaborating hospitals
either accepted central ethics approval or obtained local
approval by internal ethics committees. Because of the
nature of the retrospective study, the requirement of
informed consent was waived.
Study Sample
Only patients with a definite discharge diagnosis of STEMI
(with or without prior cardiovascular disease) were eligible for
inclusion in this study. The diagnosis of STEMI was deter-
mined by the combination of clinical discharge diagnosis
terms and ECG results. The type of AMI was validated by
review of ECG from randomly selected records by a cardiol-
ogist not involved in data abstraction, and there was a 94.7%
concordance in the selected cases (Table S1). We excluded all
patients whose STEMI occurred during the course of the
hospitalization and those who were transferred in, transferred
out, and were discharged alive in the first 24 hours of
admission (Figure S1).
Data Collection and Measures
We collected data by central abstraction of medical charts
with use of standardized data definitions, including patient
characteristics (age, cardiovascular risk factors, clinical
characteristics on presentation, and treatments) and hospi-
tal-level characteristics (acuity level, teaching status, percu-
taneous coronary intervention [PCI] capability). We compared
time from symptom onset to admission between men and
women, which included both prehospital delay and time from
arrival to admission. Admission was used to track the time of
presentation because we lacked information about time to
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presentation at the hospital. We evaluated the use of
treatments recommended by the 2010 National Guideline
for STEMI,18 which are consistent with 2007 U.S. guide-
lines.19 Rates of utilization were assessed only in patients
considered to be ideal for the treatment, defined as patients
without accepted contraindications. Criteria identifying ideal
candidates for guideline-concordant therapies are detailed in
Data S1. For the calculation of rates of diagnostic catheter-
ization and PCI, we restricted our study group to patients
admitted to facilities capable of performing PCI.
Statistical Analysis
To estimate nationally representative rates of hospitals
admission in men and women for each study year, we applied
weights proportional to the inverse sampling fraction of
hospitals within each stratum and the sampling fraction of
patients within each hospital, to account for differences in the
sampling fraction for each period. Patient characteristics and
treatments were compared between women and men, both
overall and across the 3 study years (2001, 2006, and 2011).
Categorical and continuous variables were summarized by
percentages and medians (interquartile range), respectively,
and compared using the v2 tests and Student t tests,
respectively. To examine trends across the different study
periods for each sex, we used the Mann–Kendall test for
continuous variables and the Cochran–Armitage test for
categorical variables. We investigated the association
between sex and the prevalence of cardiovascular risk
factors, adjusted for age in logistic regression models. To
examine the association between sex and treatment received,
we also adjusted for age and other baseline characteristics as
listed in Table 1 using multivariable logistic models. We
included the 2-way interaction term sex9year in the regres-
sion model to assess whether sex differences in presenting
characteristics and treatment varied by study year. All
statistical analyses were performed using SAS software
(version 9.2, SAS Institute, Cary, NC).
Results
Study Sample
We sampled 18 631 cases, from which 18 110 (97.2%) had
available records. We excluded 6645 cases that did not meet
inclusion criteria, resulting in a study sample of 11, 986
patients with STEMI (Figure S1). There were 1364, 2541, and
4507 men (representing 29 094, 65 370, and 120 991 male
patients nationally in weighted estimates) and 569, 1040, and
1965 women (representing 12 134, 27 098, and 53 585
female patients nationally in weighted estimates) in 2001,
2006, and 2011, respectively. Hospital admissions for STEMI
per 100 000 people increased 4.2-fold in men (4.6 in 2001,
10.0 in 2006, and 18.0 in 2011) and 3.9-fold in women (1.9 in
2001, 4.1 in 2006, and 8.0 in 2011).
Patients Characteristics
From 2001 to 2011, the median age of patients increased
from 68 to 72 years in women (Ptrend<0.001) but remained
stable in men (63 years in 2011) (Ptrend=0.48). The propor-
tions of men and women aged ≥80 years old significantly
increased over time (Figure 1). The prevalence of cardio-
vascular risk factors increased over time for both women
and men. Women had a higher prevalence of hypertension,
diabetes mellitus, and coronary heart disease in each time
period (P<0.001 for all comparisons) (Table 1). Similar
findings were also found in the age-adjusted results
(Figure 2). In addition, sex differences in the prevalence of
hypertension increased from 2001 to 2011, with women
having a higher prevalence. However, sex differences in the
prevalence of diabetes remained stable. Although there was
no significant sex difference in those with a low-density
lipoprotein cholesterol >130 mg/dL in 2001, this risk factor
was more prevalent in women in later time periods
(Figure 2). Women were hospitalized less often in tertiary
care hospitals and hospitals with the capacity to perform
PCI.
Women were consistently were more likely to have systolic
blood pressure over 140 mm Hg and heart rate over
100 bpm. Comparing 2001, 2006, and 2011, sex differences
in heart rate >100 bpm increased, yet differences in the
presence of systolic blood pressure measurements did not
change. Although there were significant sex differences in the
time interval of >12 hours between symptom onset and
admission time in 2001, since 2006 delays in presentation
were comparable between women and men (Figure 3). The
age-adjusted results showed that there was no sex difference
in chest discomfort in 2001 and 2006, but not 2011.
Treatment Among Ideal Candidates
The proportion of ideal patients for aspirin, clopidogrel,
b-blocker, angiotensin-converting enzyme inhibitor/an-
giotensin II receptor blocker, and statin treatments remained
unchanged over time in both sex groups (Table S2). Although
the proportion of women ideal for reperfusion therapy
increased significantly over the last decade (from 35.7% in
2001 to 43.0% in 2011, Ptrend=0.001), they remained less
likely than men (48.2%) to be ideal patients for reperfusion
therapy in 2011.
Overall, differences in treatment were consistently
observed over the study period. The absolute differences
between men and women receiving fibrinolytic therapy,
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Trends2001 (n=1364) 2006 (n=2541) 2011 (n=4507) 2001 (n=569) 2006 (n=1040) 2011 (n=1965)
Demographic
Age, y† 63 (53, 70) 64 (54, 73) 63 (53, 73) 0.476 68 (62, 74) 71 (65, 76) 72 (64, 78) <0.0001
Cardiovascular risk factors
Hypertension 38.8 45.9 47.3 <0.0001 47.8 53.4 60.6 <0.0001
Diabetes 11 15.4 18.3 <0.0001 21.1 25.8 26.9 0.010
Current smoker 38.7 41.3 48 <0.0001 6 9 11.9 <0.0001
Medical history
Coronary heart disease 22.6 19.1 20.5 0.355 26.2 22.2 21.8 0.054
Myocardial infarction 10.3 9.7 11.6 0.058 9.5 8.8 9.3 0.970
PCI 0.4 0.9 2.7 <0.0001 0.9 0.9 1.5 0.138
Stroke 9.2 10.3 11.5 0.010 10 11.7 13.9 0.070
Symptom onset to admission, hour
<6 42.2 40.9 41.3 0.467 30.9 34.1 36.9 0.003
6 to 12 hours 8.9 9.6 10.5 0.027 10.7 12.5 11.3 0.921
>12 hours 48.9 49.5 48.1 0.430 58.3 53.4 51.7 0.008
Clinical characteristics
Chest discomfort 93.1 93.2 93.4 0.652 91.2 89.7 89.3 0.219
Cardiogenic shock 3.4 5.5 6 0.0005 6.2 7.6 7.9 0.205
Cardiac arrest 0.9 1.3 1.5 0.078 0.7 0.8 1.1 0.335
Acute stroke 0.7 1.5 1 0.930 1.1 2.6 1.1 0.318
Heart rate ≥100 bpm† 15.7 14.8 11.6 <0.0001 20.2 22.0 18.4 0.098
SBP ≥140 mm Hg† 31.3 31.4 32.6 0.256 37.3 39.3 39.7 0.326
LDL-C level
<130 35.2 55.8 67.6 <0.0001 25.8 50.1 59.3 <0.0001
≥130 11.7 15.4 18.2 <0.0001 12.8 18.5 22.4 <0.0001

















Teaching hospital 85 80.6 80.1 0.0001 83.5 79.7 77.8 0.003
PCI-capable hospital 32.8 55.1 72.9 <0.0001 34.3 52.6 69 <0.0001
Hospital with CCU 81.1 76.3 79.4 0.952 78.6 77.4 78.6 0.791
Economic–geographic region
Central 19.5 21 23.2 <0.0001 16.9 17.9 22 <0.0001
Eastern 65.7 58.4 54.7 <0.0001 71.5 63.3 59.3 <0.0001
Western 14.8 20.6 22.1 <0.0001 11.6 18.8 18.7 <0.0001
Urban/rural
Urban 63.9 60.6 63.4 0.586 64 60.9 57.9 0.006
Rural 36.1 39.4 36.6 36 39.1 42.1
CCU indicates cardiac care unit; eGFR, estimated glomerular filtration rate; LDL-C, low-density lipoprotein cholesterol; PCI, percutaneous coronary intervention; SBP, systolic blood
pressure.
*Unless otherwise indicated.
†Continuous variables displayed as median values with interquartile range.
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primary PCI, or any reperfusion therapy were 6.7%, 5.5%, and
13.2% in 2011, respectively. In addition, any coronary
angiography and nonprimary PCI were performed less com-
monly during initial AMI hospitalization in women in all time
periods. Fewer women received aspirin or clopidogrel within
24 hours of admission (Table 2). After adjusting for age and
other baseline characteristics, women without contraindica-
tions to treatment were significantly less likely to receive
reperfusion therapy, coronary angiography, and nonprimary
PCI in all time periods (Table S3). No significant sex
differences were observed in the administration of other
examined medications, including b-blocker, angiotensin-con-
verting enzyme inhibitor/ angiotensin II receptor blocker, and
statin. Between 2001 and 2011, sex differences in treatment
persisted, and in some cases widened. In particular, sex
differences in the utilization of primary PCI increased
(Figure 4).
Discussion
In this large, national study in China of hospitalization for
STEMI, we found marked sex differences in clinical profiles
and quality of care. Women, who experienced a slightly higher
increase (4.2-fold versus 3.9-fold) in STEMI over the study
period, were older, had greater comorbidities, and were less
likely to be ideal patients for many evidence-based therapies.
Among ideal patients, women were significantly less likely to
receive a revascularization strategy (including fibrinolysis or
cardiac catheterization with or without PCI), even after
accounting for differences in clinical profiles. These sex-
based differences in patient characteristics and hospital care
did not change significantly over the past decade, underscor-
ing the need to specifically address these findings with quality
improvement efforts.
We had previously shown in the China PEACE study that the
risk of mortality was age dependent and most pronounced
among younger women (<70 years of age) with STEMI, even
Figure 1. Age distribution of the study sample according to sex and year.
Figure 2. Temporal trends of age-adjusted results in sex
differences in cardiovascular risk factors. LDL-C indicates low-
density lipoprotein cholesterol; OR, odds ratio.
Figure 3. Temporal trends of age-adjusted results in sex
differences in presenting characteristics. HR indicates heart rate;
OR, odds ratio; SBP, systolic blood pressure.
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after accounting for differences in clinical presentation and
treatments.3 However, we had not investigated temporal
trends in sex differences as they relate to patient character-
istics and receipt of evidence-based therapies in STEMI. We
found that even after adjusting for age, with the exception of
smoking, a predominantly male activity in China,20 risk factors
including greater age, diabetes, hypertension, and dyslipidemia
were more common in women presenting with STEMI. These
are consistent with prior national and international studies.21,22
The clinical presentation of women differed from men.
Indeed, half of the women in our study presented outside the
time window for reperfusion therapy, which is consistent over
the last decade. However, we did observe a decrease in the
delay to admission among women, and sex differences in the
time interval of >12 hours between symptom onset and
admission time disappeared since 2006, which might partly
be due to improved healthcare accessibility for women in
China.23
While the quality of care improved for both men and
women, significant sex gaps exist and have not improved over
time. Significantly fewer women received a reperfusion
strategy, even when they presented promptly for treatment.







P for TrendsMen Women 2001 2006 2011 2001 2006 2011
Acute medication
Aspirin ≤24 hours* 7023 (88.8) 2765 (85.9) <0.0001 81.1 87.7 91.8 <0.0001 78.0 85.0 88.8 <0.0001
Clopidogrel ≤24 hours* 4454 (56.9) 1679 (52.5) <0.0001 1.4 44.3 80 <0.0001 0.8 36.5 75.5 <0.0001
b-Blockers ≤24 hours* 2371 (56.8) 770 (52.6) 0.005 47.8 62.7 56.1 0.095 46.4 54.8 53.1 0.202
ACE-inhibitor/ARB*,† 5073 (65.8) 1994 (63.8) 0.044 60.8 69.6 65.2 0.214 59.2 66.7 63.6 0.332
Statin*,† 6180 (76.5) 2476 (75.1) 0.117 30.3 75.0 91.5 <0.0001 27.8 72.6 90.4 <0.0001
Reperfusion therapy†
With reperfusion 2289 (57.5) 646 (44.2) <0.0001 56.3 58.0 57.6 0.702 47.3 42.2 44.4 0.758
Primary PCI 757 (19.0) 203 (13.9) <0.0001 8.7 15.1 24.2 <0.0001 8.4 8.9 17.7 <0.0001
Fibrinolytic therapy 1535 (38.6) 443 (30.3) <0.0001 47.7 43.0 33.5 <0.0001 38.9 33.3 26.8 0.0002
Procedure‡
Nonprimary PCI 1117 (21.8) 299 (14.3) <0.0001 9.6 19.4 24.4 <0.0001 5.6 10.2 17.1 <0.0001
Cardiac catheterization 2414 (47.0) 669 (31.9) <0.0001 34.2 41.7 51.1 <0.0001 26.2 25.0 35.5 <0.0001
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; PCI, percutaneous coronary intervention.
*Only among patients without contraindications for the treatment.
†During hospitalization.
‡Only among patients admitted into a hospital capable of PCI.
Figure 4. Temporal trends of sex differences in reperfusion therapy among ideal candidates. A, Primary PCI. B, Fibrinolytic therapy. C, Any
reperfusion. PCI indicates percutaneous coronary intervention.
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Additionally, among patients deemed to be ideal candidates,
women were less likely than men to receive aspirin and
clopidogrel. Sex differences in treatment response have not
been supported by the literature; rather, prior studies indicate
that both women and men derive similar reductions in
morbidity and mortality with the prescriptions of aspirin,
clopidogrel, and with invasive cardiac procedures,4 and
guidelines do not recommend differential use of these
therapies based upon sex. The disparities in care identified
in this study require full-scale investigation into clinical
decision-making and targeted efforts to diminish such
disparities.
The rising burden of modifiable cardiovascular risk factors
among women will require local and national efforts to
advance primary and secondary prevention strategies; such
efforts may need to directly target women at high risk of heart
attack. The marked underutilization of coronary catheteriza-
tion and reperfusion therapy should prompt quality improve-
ment efforts to ensure that the evidence-based management
of STEMI is rigorously applied in patients of both sexes.24 In
the interim, large-scale educational initiatives targeting
women should be implemented in both pre-hospital and in-
hospital settings to increase women’s and their health
providers’ awareness of cardiovascular disease and recogni-
tion of symptoms of AMI,25which has been proven to be
effective in the Go Red for Women campaign, which was
initiated in the United States.25 Ultimately, dispelling myths
(or old assumptions) and improving awareness is difficult and
will require innovative, multipronged efforts.
Limitations
The results of our study should be interpreted with consid-
eration of several limitations. First, residual confounding of
measured or unmeasured variables might affect the observed
results. However, we accounted for traditional clinical factors
common among risk models predicting early mortality.
Second, given that relatively few patients underwent a cardiac
catheterization, we were not able to adjust our analysis to
account for the severity and extent of coronary artery
diseases that might contribute to the sex differences in
mortality.26 However, these data are not typically included in
risk-adjusted models, and it is not clear that anatomy would
affect in-hospital mortality differently in men and women.
Conclusions
In a large, nationally representative observational study in
China, women hospitalized with STEMI were older, had greater
delays in care seeking, more comorbidities, and worse
disease severity than men. Moreover, women were less likely
to be candidates for, and less likely to receive, evidence-
based therapies as compared with men. These disparities
have changed little over the past decade despite large-scale
efforts to increase access and quality. These findings
underscore the need for improved systems to ensure the
prompt diagnosis and use of evidence-based treatments for
women with STEMI, particularly with respect to reperfusion
therapies.
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